On October 6, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, reported that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40th Anniversary Annual Meeting, to be held 7–9 November 2025 in National Harbor, MD, USA (Press release, Alligator Bioscience, OCT 6, 2025, View Source [SID1234656454]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations will feature new data from Alligator’s pipeline programs mitazalimab and ATOR-4066:
Presentation details
Title: CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: dose characterization based on exposure response and biomarker analysis from the OPTIMIZE-1 study
Abstract number: 530
Time: Saturday, 8 November 2025
Presenter: Yago Pico de Coaña, Medical Science Director, Alligator Bioscience
Title: ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces potent anti-tumor activity that associates with activated intra-tumoral immune cells and disassembly of extracellular tumor matrix
Abstract number: 940
Time: Saturday, 8 November 2025
Presenter: Hampus Andersson, Industrial PhD student, Alligator Bioscience
"We are pleased that data for both mitazalimab and ATOR-4066 have been acknowledged through acceptance at SITC (Free SITC Whitepaper)’s 40th Anniversary Annual Meeting," said Søren Bregenholt, CEO of Alligator Bioscience. "This is an important recognition of the strength of our pipeline and our ambition to develop transformative immunotherapies for cancer patients."
The accepted abstracts will be published on 4 November 2025 at www.sitcancer.org/2025.